摘要:
Provided are methods for the treatment of SCLC patients by administering therapeutic amounts of lurbinectedin by intravenous infusion. Also provided are methods of treating cancer by administering lurbinectedin in combination with other anticancer drugs, in particular topoisomerase inhibitors. The invention further relates to the administration of lurbinectedin in combination with anti-emetic agents for effective control of symptoms related to nausea and vomiting, reduced lurbinectedin dosages to achieve a safer administration and an increase in the number of treatment cycles. Stable lyophilized formulations of lurbinectedin are also provided.
摘要:
Drug conjugates having formula [D-(X)6-(AA)w-(T)g-(L)-]n-Ab wherein: D is a drug moiety having the following formula (I) or a pharmaceutically acceptable salt, ester, solvate, tautomer or stereoisomer thereof, (I) wherein D is covalently attached via a hydroxy or amine group to (X)b if any, or (AA)w if any, or to (T)g if any, or (L); that are useful in the treatment of cancer.
摘要:
Anticancer compounds of general formula I wherein R1 to R4 take various meanings, for use in the treatment of cancer. A novel Labrenzia sp. strain named PHM005 with Accession Deposit Number CECT-9225, a method of producing compounds of the invention and analogues thereof by using the PHM005 strain and the Lab gene cluster codifying the biosynthesis of pederin-like and onnamide-like compounds are also provided.
摘要:
The present invention relates to the combination of PM01183 with several anticancer drugs, in particular other anticancer drugs selected from antitumor platinum coordination complexes, antimetabolites, mitotic inhibitors, anticancer antibiotics, topoisomerase I and/or II inhibitors, proteasome inhibitors, histone deacetylase inhibitors, nitrogen mustard alkylating agents, nitrosourea alkylating agents, nonclassical alkylating agents, estrogen antagonists, androgen antagonists, mTOR inhibitors, tyrosine kinase inhibitors, and other agents selected from aplidine, ET-743, PM02734 and PM00104, and the use of these combinations in the treatment of cancer.
摘要:
The active component of the pharmaceutical composition of the present invention is a compound which has been isolated from the controlled aerobic fermentation of a marine microorganism, Agrobacterium sp. PH-103. The pharmaceutical compositions of the present invention, useful for post surgical graft tolerance, are thus directed to compositions comprising a pharmaceutically acceptable carrier, diluent or excipient, and an effective amount of the compound having the formula: 1 This compound, known as Sesbanimide, is an alkaloid that has been previously been isolated from seeds and reported to be useful as an antitumor drug. Prior to the present invention however, this compound had not been isolated from any fermentation broth nor had it been determined to have immunomodulatory activity.